In light of the observed differences in the pattern of FGF-2 localization, the administration of agents capable of blocking both the paracrine and intracrine activities of FGF-2 in NSCLC cells has been suggested as a potential approach to cancer treatment [33]. The gene discussed is FGF2; the disease is non-small cell lung carcinoma.